Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IV

Phase 1 Completed 36 enrolled argenx

RandomizedParallel-groupOpen-labelOther

Summary

This is a randomized, open-label, placebo-controlled phase 1 study in healthy adult volunteers to provide information regarding vaccination with a common pneumococcal polysaccharide vaccine while receiving efgartigimod.

Timeline

Start: 2021-11-17
Primary completion: 2022-03-08
Completion: 2022-03-08

Publications

Azar AE, Sleasman JW, Steeland S, Verhamme FM, Winthrop KL. Humoral immune response to polyvalent pneumococcal vaccine in healthy participants receiving efgartigimod: a randomized, open-label, placebo-controlled, parallel-group phase 1 trial. Front Immunol. 2026 May 7;17:1799480. doi: 10.3389/fimmu.2026.1799480. eCollection 2026.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Efgartigimod Alfa	Protein / enzyme biologic	10 mg/kg	Intravenous
Subject	Pneumovax 23	Vaccine	—	—

Indications

No indication recorded.